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BACKGROUND
In the primary analysis of the Aspirin in Reducing Events in the Elderly (ASPREE) 
trial, now published in the Journal, we report that the daily use of aspirin did not pro-
vide a benefit with regard to the primary end point of disability-free survival among 
older adults. A numerically higher rate of the secondary end point of death from any 
cause was observed with aspirin than with placebo.
METHODS
From 2010 through 2014, we enrolled community-dwelling persons in Australia 
and the United States who were 70 years of age or older (or ≥65 years of age among 
blacks and Hispanics in the United States) and did not have cardiovascular disease, 
dementia, or disability. Participants were randomly assigned to receive 100 mg of 
enteric-coated aspirin or placebo. Deaths were classified according to the underlying 
cause by adjudicators who were unaware of trial-group assignments. Hazard ratios 
were calculated to compare mortality between the aspirin group and the placebo 
group, and post hoc exploratory analyses of specific causes of death were performed.
RESULTS
Of the 19,114 persons who were enrolled, 9525 were assigned to receive aspirin 
and 9589 to receive placebo. A total of 1052 deaths occurred during a median of 
4.7 years of follow-up. The risk of death from any cause was 12.7 events per 1000 
person-years in the aspirin group and 11.1 events per 1000 person-years in the pla-
cebo group (hazard ratio, 1.14; 95% confidence interval [CI], 1.01 to 1.29). Cancer 
was the major contributor to the higher mortality in the aspirin group, accounting 
for 1.6 excess deaths per 1000 person-years. Cancer-related death occurred in 3.1% 
of the participants in the aspirin group and in 2.3% of those in the placebo group 
(hazard ratio, 1.31; 95% CI, 1.10 to 1.56).
CONCLUSIONS
Higher all-cause mortality was observed among apparently healthy older adults who 
received daily aspirin than among those who received placebo and was attributed 
primarily to cancer-related death. In the context of previous studies, this result was 
unexpected and should be interpreted with caution. (Funded by the National Insti-
tute on Aging and others; ASPREE ClinicalTrials.gov number, NCT01038583.)
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The Aspirin in Reducing Events in the Elderly (ASPREE) trial was a primary prevention trial that was established to 
investigate whether the daily use of 100 mg of 
enteric-coated aspirin would prolong the healthy 
life span of older adults.1,2 The trial, which was 
conducted in Australia and the United States, 
recruited 19,114 relatively healthy older persons 
from community settings. The primary end point 
was disability-free survival, which was defined as 
survival free from dementia or persistent physical 
disability. The primary composite end point was 
derived from the first end-point events of death, 
dementia, and persistent physical disability. The 
use of low-dose aspirin did not differ signifi-
cantly from placebo in influencing the rate of the 
primary end point after a median of 4.7 years of 
follow-up.
When we took into account all occurrences of 
death, dementia, or persistent physical disability 
(regardless of whether they contributed to the pri-
mary composite end point), the incidence of each 
individual component did not differ significantly 
between the two trial groups. Overall mortality 
was higher in the aspirin group than in the pla-
cebo group, but not to an extent that reached sig-
nificance if the P value was corrected for multiple 
comparisons. Other primary prevention trials of 
aspirin have not identified similar higher all-cause 
mortality.3-12 In this article, we examine the higher 
mortality in the aspirin group of the ASPREE trial, 
focusing on specific causes of death.
Me thods
Trial Design
The trial involved men and women from Australia 
and the United States who were 70 years of age or 
older (or ≥65 years of age among blacks and His-
panics in the United States) (Tables S1 and S2 in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org). Details re-
garding the trial methods have been published 
previously,13 and the protocol is available at NEJM 
.org. In brief, participants were randomly assigned 
to receive 100 mg of enteric-coated aspirin daily 
or matching placebo. In Australia, recruitment in-
volved collaboration with the participant’s usual 
primary care physician. In the United States, re-
cruitment was community-based through aca-
demic health centers. The trial intervention was 
stopped on June 12, 2017, at the request of the 
funding agency, the National Institute on Aging, 
because results of conditional power analyses 
indicated that it was extremely unlikely that con-
tinuation of the trial intervention would reveal a 
benefit with regard to the primary end point.1 
The decision was made during regular monitor-
ing of trial progress and was not part of a pre-
planned interim analysis. All the results reported 
in this article were based on deaths that occurred 
in participants before the date of cessation of the 
trial intervention.
Notification of Death during the Trial
During the trial, participants were contacted by 
telephone quarterly and were asked to attend face-
to-face visits annually. Examination of clinical re-
cords was performed in conjunction with these 
visits. In most cases, death was identified during 
the course of routine trial activity, when failure 
to establish contact led to a review of health re-
cords or when the next of kin or a close contact 
notified the trial center. In all cases, notification 
of death required confirmation from two indepen-
dent sources (the family, the primary care physi-
cian, or a public death notice).
In Australia, to supplement these strategies, 
the trial staff performed weekly linkage with the 
Ryerson Index, a community-maintained register 
that is compiled by volunteers who monitor death 
notices and obituaries.14 At the end of the trial, 
the names of all the Australian participants, as 
well as the names of U.S. participants who had 
withdrawn or were lost to follow-up, were linked 
to the National Death Index in the relevant country.
Adjudication of the Underlying Cause  
of Death
After a notification of death was confirmed, clini-
cal details related to the death were sought from 
clinicians, hospitals, nursing homes, and hospices. 
The information that was compiled included 
autopsy reports, hospital progress notes and 
discharge summaries, and information obtained 
from the next of kin or other family members. A 
copy of the death certificate was requested from 
the relevant government agency (state-based reg-
isters of births, deaths, and marriages).
From these documents, staff at the trial coor-
dinating center at Monash University prepared 
case summaries that were presented to two ad-
judicators, one in the United States and one in 
Australia. The staff members and the adjudica-
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tors were unaware of the trial-group assignments. 
The adjudicators examined the progression of the 
final illness or incident and assigned an underly-
ing cause of death, which was considered to be 
the single disease that was most likely to have 
initiated the trajectory toward death. Discordant 
adjudications were resolved through consensus. 
In cases of death in which relevant records could 
not be obtained, the underlying cause of death 
was based on International Classification of Diseases, 
10th Revision (ICD-10), codes that were recorded 
on the death certificate or on the results of a 
search of the National Death Index.
Determination of the Proximal Cause  
of Death
In addition to the underlying cause of death, the 
proximal cause of death was determined. Avail-
able clinical documentation was examined by 
clinical trial staff who were unaware of the trial-
group assignments. The proximal cause of death 
was considered to be the terminal event that im-
mediately led to death (e.g., infection, bleeding, 
or thrombosis). In an independent assessment 
of cancer-related causes of death, we tabulated 
information from death certificates to deter-
mine whether cancer was listed as a contribut-
ing cause (Tables S4 and S5 in the Supplemen-
tary Appendix).
Statistical Analysis
All analyses were performed on an intention-to-
treat basis. Cox proportional-hazards models were 
used to compare results between the aspirin group 
and the placebo group. Hazard ratios were calcu-
lated for death from any cause and for death re-
lated to specific causes. Analyses of subgroups 
that were defined according to prespecified (and 
some nonprespecified) baseline characteristics 
were performed with inclusion of interactions in 
the Cox models. Further details about the analyses 
are available in the statistical analysis plan.15 Cu-
mulative incidences were used to show the risk of 
death related to each specific cause, with stratifi-
cation according to trial group and with allow-
ance for the competing risk of death from the 
other causes.16 Confidence intervals and P values 
were not adjusted for multiple comparisons.
R esult s
Participants
From March 2010 through December 2014, a total 
of 19,114 persons (16,703 from Australia and 2411 
from the United States) were enrolled in the trial, 
of whom 9525 were randomly assigned to receive 
aspirin and 9589 to receive placebo. Details regard-
ing the characteristics of the participants have 
been published previously.17 Blacks and Hispanics 
Cause of Death
Overall  
(N = 19,114)
Aspirin 
(N = 9525)
Placebo 
(N = 9589)
Hazard Ratio 
(95% CI)
no. of deaths no. of deaths (%)
Any 1052 558 (5.9) 494 (5.2) 1.14 (1.01–1.29)
Cancer† 522 295 (3.1) 227 (2.3) 1.31 (1.10–1.56)
Cardiovascular disease, including ischemic stroke‡ 203 91 (1.0) 112 (1.2) 0.82 (0.62–1.08)
Major hemorrhage, including hemorrhagic stroke§ 53 28 (0.3) 25 (0.3) 1.13 (0.66–1.94)
Other¶ 262 140 (1.5) 122 (1.3) 1.16 (0.91–1.48)
Insufficient information‖ 12 4 (<0.1) 8 (0.1) —
*  The confidence intervals shown in this table have not been adjusted for multiple comparisons, and inferences drawn from them may not be 
reproducible.
†  Data are shown for deaths that were related to primary or metastatic cancer.
‡  Cardiovascular disease was defined as any ischemic event (myocardial infarction, other coronary heart disease, sudden cardiac death, or 
ischemic stroke).
§  Major hemorrhage was defined as any hemorrhagic event (hemorrhagic stroke, symptomatic intracranial bleeding, or major gastrointestinal 
bleeding or other extracranial bleeding).2
¶  Data are shown for deaths that were related to causes that are not represented in the other categories (e.g., sepsis, chronic lung disease, 
dementia, or heart failure), except for deaths for which insufficient information was available to adjudicate an underlying cause.
‖  Data are shown for deaths for which insufficient information was available to adjudicate an underlying cause, even after linkage with the 
National Death Index. The hazard ratio was not determined because of the low numbers of deaths.
Table 1. Mortality According to the Underlying Cause of Death.*
The New England Journal of Medicine 
 
 Copyright © 2018 Massachusetts Medical Society. All rights reserved. 
n engl j med nejm.org 4
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
constituted 52.7% of the 2411 trial participants 
from the United States. At the end of the trial, 
the total number of years during which partici-
pants were at risk for death (person-years) was 
44,007 in the aspirin group and 44,382 in the 
placebo group.
All-Cause Mortality
A total of 1052 participants (5.5%) died during the 
trial. The analysis of the secondary end point of 
death from any cause included the 141 deaths that 
occurred after another primary end-point event 
(i.e., a diagnosis of dementia or permanent physi-
cal disability). The risk of death from any cause 
was 12.7 events per 1000 person-years in the 
aspirin group and 11.1 events per 1000 person-
years in the placebo group (hazard ratio, 1.14; 
95% confidence interval [CI], 1.01 to 1.29), with 
1.6 excess deaths per 1000 person-years in the as-
pirin group. Table 1 shows the risk of death ac-
cording to the major underlying causes (cancer, 
cardiovascular disease, and major hemorrhage), 
Figure 1. Cumulative Incidence of Death According to the Underlying Cause.
Shown is the cumulative incidence of death according to major underlying causes (cancer, cardiovascular disease, and major hemor-
rhage) and of death related to other causes. For each cause of death, the cumulative incidence was based on a competing-risks model, 
which was stratified according to trial group, with the remaining causes of death as competing events. Data are not shown for 12 deaths 
for which insufficient information was available to adjudicate an underlying cause, even after linkage with the National Death Index. The 
insets show the same data on an enlarged y axis.
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as well as the risk of death related to other causes, 
such as sepsis, chronic lung disease, dementia, or 
heart failure.
Cancer was the underlying cause in 49.6% of 
the deaths, cardiovascular disease (including 
ischemic stroke) in 19.3%, and major hemor-
rhage (including hemorrhagic stroke) in 5.0% 
(Table 1). In only 12 cases of death (4 in the 
aspirin group and 8 in the placebo group), insuf-
ficient information was available to allow an un-
derlying cause to be determined. A total of 97.6% 
of the deaths were detected during the trial, with 
2.4% (25 deaths) identified during the final search 
of the National Death Index.
Cancer-Related Mortality
Among participants who received aspirin, the 
major contributor to the higher all-cause mortal-
ity was the higher risk of death for which the 
underlying cause was adjudicated to be cancer. 
The risk of cancer-related death was 6.7 events per 
1000 person-years in the aspirin group and 5.1 
events per 1000 person-years in the placebo group 
(hazard ratio, 1.31; 95% CI, 1.10 to 1.56) (Table S3 
in the Supplementary Appendix). In a separate 
analysis that was based on a tabulation of the 
number of deaths in which cancer was recorded 
as a contributing cause on the death certificate, 
a similar pattern was observed, with 272 deaths 
(6.2 events per 1000 person-years) in the aspirin 
group and 206 deaths (4.6 events per 1000 per-
son-years) in the placebo group. In curves show-
ing the cumulative incidence of death according 
to each major cause, there is a progressive diver-
gence beginning in the third year after random-
ization in the curves for death from any cause1 
and for death related to cancer, as compared 
with the curves for death related to other major 
causes (Fig. 1).
Table 2 shows cancer-related mortality ac-
cording to the type of cancer. Despite the small 
number of deaths associated with each type of 
Type of Cancer
Aspirin 
(N = 9525)
Placebo 
(N = 9589)
Hazard Ratio 
(95% CI)
no. of 
 deaths
rate per  
1000 person-yr
no. of 
 deaths
rate per  
1000 person-yr
Any 295 6.7 227 5.1 1.31 (1.10–1.56)
Lung 55 1.3 51 1.2 1.09 (0.74–1.59)
Colorectal 35 0.8 20 0.5 1.77 (1.02–3.06)
Pancreatic 29 0.7 21 0.5 1.40 (0.80–2.45)
Hematologic 24 0.6 19 0.4 1.27 (0.70–2.33)
Prostate 18 0.4 17 0.4 1.07 (0.55–2.08)
Ovarian or endometrial 15 0.3 13 0.3 1.16 (0.55–2.45)
Breast 15 0.3 7 0.2 2.16 (0.88–5.31)
Brain 13 0.3 9 0.2 1.46 (0.62–3.41)
Melanoma 12 0.3 8 0.2 1.51 (0.62–3.70)
Bladder 8 0.2 9 0.2 —
Kidney 9 0.2 4 0.1 —
Gallbladder or bile duct 7 0.2 6 0.1 —
Stomach 9 0.2 3 0.1 —
Liver 4 0.1 0 0 —
Other 28 0.6 27 0.6 1.05 (0.62–1.78)
Unknown primary 12 0.3 7 0.2 1.73 (0.68–4.39)
Undetermined 2 0.05 6 0.1 —
*  Some hazard ratios were not determined because of the low numbers of deaths. The confidence intervals shown in this 
table have not been adjusted for multiple comparisons, and inferences drawn from them may not be reproducible.
Table 2. Cancer-Related Mortality According to Type of Cancer.*
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cancer, it is apparent that the higher cancer-relat-
ed mortality in the aspirin group was not con-
fined to specific tumor locations or pathologic 
types. A higher rate of death from gastrointestinal 
cancer (including colorectal cancer) in the aspirin 
group than in the placebo group contributed sub-
stantially to the overall excess mortality associated 
with aspirin. The excess cancer-related mortality 
among participants who received aspirin was seen 
both among those who entered the trial with a 
personal history of cancer (with cancer-related 
death occurring in 94 such participants in the as-
pirin group and in 88 in the placebo group) and 
among those in whom cancer was first diagnosed 
0.750.50 1.00 1.33 2.00 3.00
Placebo BetterAspirin Better
Overall
Sex
Male
Female
Age
65–73 yr
≥74 yr
Country
Australia
United States
Race or ethnic group
White
Australia
United States
Black
Hispanic
Other
Diabetes mellitus
No
Yes
Hypertension
No
Yes
Smoking status
Current
Former
Never
Previous regular aspirin use
No
Yes
Frailty
Not frail
Prefrail
Frail
Personal history of cancer
No
Yes
Dyslipidemia
No
Yes
Body-mass index
<20, Underweight
20–24, Normal weight
25–29, Overweight
≥30, Obese
Aspirin Hazard Ratio (95% CI)PlaceboSubgroup
1.14 (1.01–1.29)
1.19 (1.01–1.40)
1.09 (0.91–1.30)
1.09 (0.87–1.36)
1.15 (1.00–1.33)
1.21 (1.06–1.37)
0.79 (0.57–1.11)
1.20 (1.05–1.36)
0.84 (0.52–1.38)
0.78 (0.45–1.33)
0.72 (0.32–1.61)
2.05 (0.69–6.13)
1.11 (0.98–1.27)
1.33 (0.97–1.82)
1.15 (0.89–1.49)
1.14 (0.99–1.31)
0.91 (0.61–1.36)
1.28 (1.07–1.53)
1.08 (0.90–1.29)
1.19 (1.05–1.36)
0.86 (0.62–1.19)
1.26 (1.04–1.53)
1.03 (0.88–1.22)
1.36 (0.85–2.19)
1.14 (0.99–1.31)
1.14 (0.91–1.44)
1.11 (0.92–1.35)
1.15 (0.99–1.35)
1.33 (0.75–2.35)
0.98 (0.78–1.23)
1.10 (0.91–1.33)
1.38 (1.08–1.77)
0.33
P Value for
Interaction
No. of
Participants
558 (12.7)
314 (16.6)
244 (9.7)
154 (7.2)
404 (18.0)
496 (13.1)
  62 (10.3)
486 (13.0)
  29 (9.7)
  24 (12.0)
  10 (9.0)
    9 (15.3)
471 (11.9)
  87 (19.4)
125 (11.0)
433 (13.3)
  43 (28.0)
272 (15.2)
243 (9.9)
488 (12.6)
  70 (13.1)
228 (8.9)
289 (16.7)
  41 (42.6)
398 (11.1)
157 (19.3)
224 (14.9)
334 (11.5)
  29 (33.5)
148 (13.8)
228 (11.7)
150 (11.7)
19,114
8,331
10,783
9,542
9,572
16,703
2,411
16,362
1,088
901
488
275
17,057
2,057
4,919
14,195
735
7,799
10,580
17,018
2,094
11,246
7,447
421
15,375
3,660
13,135
5,979
352
4,526
8,480
5,677
494 (11.1)
269 (14.1)
225 (8.9)
145 (6.6)
349 (15.6)
416 (10.8)
  78 (13.0)
410 (10.9)
  35 (11.5)
  30 (15.3)
  14 (12.3)
    5 (7.3)
426 (10.7)
  68 (15.0)
109 (9.6)
385 (11.7)
  52 (30.8)
217 (12.0)
225 (9.1)
415 (10.6)
  79 (15.2)
183 (7.0)
282 (16.1)
  29 (31.6)
353 (9.8)
139 (17.0)
196 (13.4)
298 (10.0)
  20 (25.0)
147 (14.0)
213 (10.7)
111 (8.5)
0.46
0.66
0.02
0.19
0.31
0.94
0.23
0.07
0.22
0.97
0.78
0.22
no. of events
(rate per 1000 person-yr)
Lorem ipsum
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after randomization (with cancer-related death oc-
curring in 198 and 138, respectively) (Table S3 in 
the Supplementary Appendix).
The higher cancer-related mortality among 
those who received aspirin was accompanied by a 
higher incidence of cancer among those who re-
ceived aspirin, although to a lesser degree: cancer 
(excluding nonmelanoma skin cancer) was diag-
nosed in 981 participants in the aspirin group, as 
compared with 952 in the placebo group. Among 
the 66% of deaths for which information regard-
ing the terminal phase of the illness was available, 
there were no apparent differences between the 
two trial groups in the rate of each proximal cause 
of death, including bleeding (Tables S4 and S5 in 
the Supplementary Appendix).
Subgroup Analyses
The effect of aspirin on all-cause mortality ap-
peared to be consistent across a series of prespeci-
fied and nonprespecified subgroups (Fig. 2, and 
Fig. S1 and Table S6 in the Supplementary Appen-
dix). The only significant interaction term was 
country of origin (P = 0.02); the effect of aspirin on 
mortality appeared to be limited to Australian 
participants. Interpretation of this interaction is 
limited because P values were not adjusted for 
multiple comparisons and is complicated by dif-
ferences between participants from the two coun-
tries in age and race (and possibly other factors).
Figure S2 and Table S3 in the Supplementary 
Appendix show the difference between the aspi-
rin group and the placebo group in cancer-related 
mortality according to a variety of prespecified 
and nonprespecified subgroups. There was no 
evidence of a modification in the effect of aspirin 
on cancer-related mortality among the examined 
subgroups.
In addition, Figure S3 in the Supplementary 
Appendix shows the hazard ratios for all-cause 
mortality for aspirin as compared with placebo 
that were reported in other major primary preven-
tion trials involving this agent. The higher mor-
tality in the aspirin group in this trial was an 
unexpected result in the context of previous trials.
Mortality in the Trial Population  
as Compared with the General Population
As a frame of reference, we examined all-cause 
mortality and cancer-related mortality in a simu-
lated cohort of the general population that was 
matched to the trial population in age, sex, coun-
try of origin, and race or ethnic group (with data 
for the final characteristic available only for the 
U.S. participants). All-cause mortality was 34.9 
events per 1000 person-years in the matched popu-
lation, as compared with 11.1 events per 1000 
person-years in the trial population. Cancer-relat-
ed mortality was 10.5 events per 1000 person-
years in the matched population, as compared with 
5.1 events per 1000 person-years in the trial popu-
lation.
Discussion
In the randomized, placebo-controlled ASPREE 
trial, the use of low-dose aspirin (100 mg per day 
for a median of 4.7 years) did not prolong dis-
ability-free survival among elderly participants, 
most of whom were 70 years of age or older at 
trial entry.1 Death from any cause, which was a 
component of the primary end point (disability-
free survival) as well as a secondary end point, 
occurred in 558 participants in the aspirin group 
(at a rate of 12.7 events per 1000 person-years) and 
Figure 2 (facing page). Subgroup Analyses of All-Cause 
Mortality.
Race and ethnic group were reported by the participants. 
Other race or ethnic group was defined as any category 
with less than 200 participants overall, which included 
Aboriginal or Torres Strait Islander (12 participants), 
Native American (6), multiple races or ethnic groups 
(64), Native Hawaiian or Pacific Islander (11), and those 
who indicated that they were not Hispanic but did not 
state another race or ethnic group (18). The arrows in-
dicate that the 95% confidence intervals were beyond 
the scale. The presence of diabetes was based on par-
ticipants’ report of diabetes mellitus or a fasting glu-
cose level of at least 126 mg per deciliter (≥7 mmol 
per liter) or receipt of treatment for diabetes. Hyper-
tension was defined as treatment for high blood pres-
sure or a blood pressure of more than 140/90 mm Hg 
at trial entry. Previous regular aspirin use was defined 
according to participant-reported regular use of aspi-
rin immediately before the first baseline visit, with a 
1-month washout period before randomization. Frailty 
was categorized on the basis of the adapted Fried 
frailty criteria, which included body weight, strength, 
exhaustion, walking speed, and physical activity.15 The 
category of prefrail included participants who met one 
or two criteria, and the category of frail included those 
who met three or more criteria. Dyslipidemia was de-
fined as the receipt of cholesterol-lowering medication 
or as a serum cholesterol level of at least 212 mg per 
deciliter (≥5.5 mmol per liter) in Australia and at least 
240 mg per deciliter (≥6.2 mmol per liter) in the Unit-
ed States or as a low-density lipoprotein level of more 
than 160 mg per deciliter (>4.1 mmol per liter). Body-
mass index is the weight in kilograms divided by the 
square of the height in meters.
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in 494 participants in the placebo group (at a rate 
of 11.1 events per 1000 person-years), with a haz-
ard ratio of 1.14. The 95% confidence interval for 
the hazard ratio was 1.01 to 1.29. However, the 
calculation of the confidence interval did not 
account for the fact that multiple secondary end 
points were analyzed. Nevertheless, the results 
could not rule out an increase of 1 to 29% in all-
cause mortality.
The apparent higher mortality in the aspirin 
group than in the placebo group was explained 
largely by higher cancer-related mortality in the 
aspirin group, with mortality related to major 
hemorrhage contributing only minimally. Cumu-
lative incidence curves for death from any cause1 
and cancer-related death were similar in the as-
pirin group and the placebo group during the 
first 3 years of the trial. Beyond that time, the 
curves for these end points in the aspirin group 
appeared to diverge progressively from the curves 
in the placebo group, whereas the curves for 
death related to other major causes were similar 
in the two groups. In an exploratory analysis, the 
hazard ratio for cancer-related death was 1.31 
(95% CI, 1.10 to 1.56).
All-cause mortality and cancer-related mor-
tality in the trial population were 32% and 49% 
of the rates in the general population, respectively. 
The lower rates in the trial population probably 
reflect the healthy nature of the trial volunteers 
and the exclusion of participants with previous 
cardiovascular or cerebrovascular disease, cog-
nitive impairment, or a physician-estimated life 
expectancy of less than 5 years.
In the context of multiple end points, the 
clinical importance of the between-group differ-
ences in death from any cause and cancer-related 
death is uncertain. However, the relatively large 
number of events, the objective nature of the end 
points with virtually complete ascertainment of 
vital status, and the progressive separation of 
the cumulative incidence curve for cancer-related 
death in the aspirin group from the curve in the 
placebo group are in favor of a true effect.
The higher cancer-related mortality in the 
aspirin group was not confined to any specific 
cancer location or pathologic type and was ob-
served among both Australian and U.S. partici-
pants (Fig. S2 in the Supplementary Appendix). 
It could not be associated with a particular proxi-
mal cause of death, such as bleeding, which was 
observed rarely among the participants for whom 
data regarding the terminal phase of illness were 
available (Table S5 in the Supplementary Appen-
dix). In fact, most participants would have stopped 
taking the trial intervention in advance of the 
terminal phase of their last illness, making it 
unlikely that aspirin would have contributed to 
higher mortality at that stage.
Primary prevention trials of low-dose aspirin 
that have been published previously have not 
shown similar higher mortality. In addition, these 
trials have not shown higher cancer-related mor-
tality, although most previous studies did not in-
clude cancer as a predefined secondary end point 
and did not institute systematic approaches to the 
diagnosis and adjudication of cancer end points. 
These trials also differed from the ASPREE trial 
in their inclusion of relatively small numbers of 
participants 70 years of age or older. In our trial, 
tumor-tissue samples at diagnosis were obtained 
from approximately half the participants in whom 
cancer developed and may be useful in further 
exploration of the biologic mechanisms involved.18
In contrast to the ASPREE trial, meta-analyses 
of previous randomized prevention trials of as-
pirin have shown a protective effect of aspirin on 
cancer-related death, which became evident after 
4 or 5 years of continuous therapy.19 Despite lim-
ited periods of intervention (typically ≤5 years), 
the preventive effect of aspirin was maintained 
for at least 15 years. There was also evidence of 
a lower risk of death from metastatic spread of 
cancer among participants who received aspirin 
than among those who received placebo.20
The biologic basis for either an early or a de-
layed effect of aspirin on cancer is unclear. Aspi-
rin has been shown to influence various cellular 
and molecular pathways that are relevant to the 
initiation, progression, and spread of cancer.21 
Questions may therefore arise about whether the 
biology of cancer differs among age groups with 
regard to the frequency of common molecular 
patterns, metastatic behavior, and treatment re-
sponses.
Strengths of the data on mortality in this 
trial include the size of the trial sample, particu-
larly the large number of participants 70 years of 
age or older, and the access to clinical records, 
which allowed the underlying and proximal causes 
of death to be identified accurately in a high per-
centage of cases, despite the complex clinical sce-
narios that are common in this age group. The 
principal limitation is the limited follow-up pe-
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riod, which may have ended before the possible 
emergence of a preventive effect on cancer. The 
trial also focused on a specific age range and had 
limited statistical power on which to base firm 
conclusions about the effect of aspirin on mortal-
ity in subgroups of the U.S. population.
In conclusion, among healthy adults who did 
not have an indication for aspirin use and were 
predominantly 70 years of age or older at enroll-
ment, all-cause mortality was apparently higher 
among those who received daily low-dose aspirin 
than among those who received placebo, with 1.6 
excess deaths per 1000 person-years occurring in 
the aspirin group after a median of 4.7 years, and 
cancer was the principal cause of the excess 
deaths. Other primary prevention trials of aspirin 
have not identified similar results, which suggests 
that the mortality results reported here should be 
interpreted with caution.
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